Bavarian Nordic Beheer

Beheer criteriumcontroles 3/4

De CEO Bavarian Nordic is Paul Chaplin, benoemd in Jun2014, heeft een ambtstermijn van 10.42 jaar. De totale jaarlijkse vergoeding van { bedraagt DKK 23.43M, bestaande uit 30.7% salaris en 69.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.11% van de aandelen van het bedrijf, ter waarde € 2.10M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.8 jaar en 3.8 jaar.

Belangrijke informatie

Paul Chaplin

Algemeen directeur

DKK 23.4m

Totale compensatie

Percentage CEO-salaris	30.7%
Dienstverband CEO	10.4yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	4.8yrs
Gemiddelde ambtstermijn bestuur	3.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Paul Chaplin's beloning veranderd ten opzichte van Bavarian Nordic's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	DKK 1b
Jun 30 2024	n/a	n/a	DKK 707m
Mar 31 2024	n/a	n/a	DKK 984m
Dec 31 2023	DKK 23m	DKK 7m	DKK 1b
Sep 30 2023	n/a	n/a	DKK 723m
Jun 30 2023	n/a	n/a	DKK 1b
Mar 31 2023	n/a	n/a	DKK 301m
Dec 31 2022	DKK 22m	DKK 6m	-DKK 347m
Sep 30 2022	n/a	n/a	-DKK 599m
Jun 30 2022	n/a	n/a	-DKK 693m
Mar 31 2022	n/a	n/a	-DKK 606m
Dec 31 2021	DKK 18m	DKK 6m	-DKK 465m
Sep 30 2021	n/a	n/a	-DKK 737m
Jun 30 2021	n/a	n/a	-DKK 629m
Mar 31 2021	n/a	n/a	-DKK 368m
Dec 31 2020	DKK 14m	DKK 5m	DKK 278m
Sep 30 2020	n/a	n/a	DKK 606m
Jun 30 2020	n/a	n/a	DKK 481m
Mar 31 2020	n/a	n/a	DKK 267m
Dec 31 2019	DKK 12m	DKK 5m	-DKK 347m
Sep 30 2019	n/a	n/a	-DKK 402m
Jun 30 2019	n/a	n/a	-DKK 271m
Mar 31 2019	n/a	n/a	-DKK 279m
Dec 31 2018	DKK 12m	DKK 6m	-DKK 362m
Sep 30 2018	n/a	n/a	-DKK 445m
Jun 30 2018	n/a	n/a	-DKK 151m
Mar 31 2018	n/a	n/a	DKK 5m
Dec 31 2017	DKK 13m	DKK 5m	DKK 181m

Compensatie versus markt: De totale vergoeding ($USD 3.31M ) Paul } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.61M ).

Compensatie versus inkomsten: De vergoeding van Paul is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Paul Chaplin (57 yo)

10.4yrs

Tenure

DKK 23,428,000

Compensatie

Dr. Paul John Chaplin, M.Sc., Ph D., has been the Chief Executive Officer and President at Bavarian Nordic A/S since May 28, 2014. Dr. Chaplin served as an Executive Vice President of Bavarian Nordic A/S f...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Paul Chaplin	CEO & President	10.4yrs	DKK 23.43m	0.11% € 1.9m
Henrik Juuel	CFO & Executive VP	6yrs	DKK 12.23m	geen gegevens
Russell Thirsk	Executive VP & COO	2.6yrs	geen gegevens	geen gegevens
Rolf Sørensen	Vice President of Investor Relations & Communications	no data	geen gegevens	geen gegevens
Anu Kerns	Executive VP and Chief People & Sustainability Officer	4yrs	geen gegevens	geen gegevens
Jean-Christophe May	Executive VP & Chief Commercial Officer	4.8yrs	geen gegevens	geen gegevens

4.8yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BV3 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Peter Kürstein-Jensen	Independent Director	12.6yrs	DKK 740.00k	0.026% € 466.1k
Anders Pedersen	Deputy Chairman	14.6yrs	DKK 1.13m	0.024% € 430.0k
Franciscus A. G. Verwiel	Independent Director	8.6yrs	DKK 830.00k	0.0055% € 97.8k
Anne Eberhard	Independent Director	5.6yrs	DKK 860.00k	0.0034% € 61.4k
Luc Debruyne	Independent Chairman	1.7yrs	DKK 1.43m	geen gegevens
Heidi Hunter	Independent Director	1.8yrs	DKK 635.00k	geen gegevens
Linette Munksgaard Andersen	Employee-Elected Member of the Board	3.8yrs	DKK 475.00k	0.00070% € 12.5k
Thomas Alex Bennekov	Employee-Elected Member of the Board	3.8yrs	DKK 475.00k	0.0024% € 42.2k
Anja Gjol	Employee-Elected Member of the Board	3.8yrs	DKK 475.00k	0.00070% € 12.5k
Karen Merete Jensen	Employee-Elected Member of the Board	3.8yrs	DKK 475.00k	0.00062% € 11.0k
Johan Hoof	Independent Director	1.8yrs	DKK 575.00k	geen gegevens
Montse Picart	Independent Director	less than a year	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BV3 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bavarian Nordic Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

CEO & President recently sold €3.2m worth of stock

Bavarian Nordic A/S, Annual General Meeting, Apr 09, 2025

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Chairman recently sold €68k worth of stock

Less than half of directors are independent

Recent updates

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: EPS: kr.0.90 (vs kr.4.40 loss in 3Q 2023)

Investor sentiment deteriorates as stock falls 17%

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic's Mpox Vaccine

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

CEO & President recently sold €3.2m worth of stock

Investor sentiment deteriorates as stock falls 16%

Bavarian Nordic A/S Announces First Doses of its Mpox Vaccine, Mva-BN

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Singapore

Bavarian Nordic A/S, Annual General Meeting, Apr 09, 2025

Second quarter 2024 earnings released

Bavarian Nordic A/S to Report Fiscal Year 2024 Results on Mar 05, 2025

Bavarian Nordic A/S Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents

Investor sentiment improves as stock rises 34%

New major risk - Share price stability

Bavarian Nordic A/S Receives Positive Chmp Opinion for Including Mpox Real-World Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine

Bavarian Nordic A/S Receives EMA Filing Acceptance and Validation of the MAA for Its Chikungunya Vaccine

Investor sentiment improves as stock rises 23%

Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

First quarter 2024 earnings released: kr.1.50 loss per share (vs kr.5.10 profit in 1Q 2023)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: kr.19.20 (vs kr.4.93 loss in FY 2022)

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: kr.4.40 loss per share (vs kr.0.20 profit in 3Q 2022)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Investor sentiment improves as stock rises 17%

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Investor sentiment improves as stock rises 15%

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 24%

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Now 22% undervalued

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Chairman recently sold €68k worth of stock

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: kr.0.20 (vs kr.1.30 loss in 3Q 2021)

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Second quarter 2022 earnings released: kr.3.40 loss per share (vs kr.2.40 loss in 2Q 2021)

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate

Bavarian Nordic A/S Revises Revenue Guidance for the Year 2022